Literature DB >> 18272687

Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens.

Jonathan P Britt1, Daniel S McGehee.   

Abstract

Behaviorally relevant stimuli prompt midbrain dopamine (DA) neurons to switch from tonic to burst firing patterns. Similar shifts to burst activity are thought to contribute to the addictive effects of opiates and nicotine. The nucleus accumbens DA overflow produced by these drugs is a key element in their pathological effects. Using electrochemical techniques in brain slices, we explored the effects of opioids on single-spike and burst stimuli-evoked DA overflow in the dorsal and ventral striatum. In specific subregions of the nucleus accumbens, mu-opioids inhibit DA overflow elicited with single-spike stimuli while leaving that produced by burst stimuli unaffected. This is similar to published effects of nicotinic receptor blockade or desensitization, and is mediated by opioid receptor-induced inhibition of cholinergic interneurons. Whereas delta-opioids have similar effects, kappa-opioids inhibit evoked DA overflow throughout the striatum in a manner that is not overcome with high-frequency stimuli. These observations reveal remarkable mechanistic overlap between the effects of nicotine and opiates within the dopamine reward pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272687      PMCID: PMC6671549          DOI: 10.1523/JNEUROSCI.4275-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

1.  μ- and δ-opioid-related processes in the accumbens core and shell differentially mediate the influence of reward-guided and stimulus-guided decisions on choice.

Authors:  Vincent Laurent; Beatrice Leung; Nigel Maidment; Bernard W Balleine
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

Review 2.  Dissecting motivational circuitry to understand substance abuse.

Authors:  Robert A Wheeler; Regina M Carelli
Journal:  Neuropharmacology       Date:  2008-06-25       Impact factor: 5.250

3.  Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal.

Authors:  Aya Matsui; Brooke C Jarvie; Brooks G Robinson; Shane T Hentges; John T Williams
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

4.  MSI-1436 reduces acute food intake without affecting dopamine transporter activity.

Authors:  Mitchell F Roitman; Seth Wescott; Jackson J Cone; Michael P McLane; Henry R Wolfe
Journal:  Pharmacol Biochem Behav       Date:  2010-05-15       Impact factor: 3.533

Review 5.  Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits.

Authors:  Huibert D Mansvelder; Marjolijn Mertz; Lorna W Role
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

Review 6.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 7.  Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices.

Authors:  Mark J Ferris; Erin S Calipari; Jordan T Yorgason; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2013-05-06       Impact factor: 4.418

8.  Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.

Authors:  Rosemarie A Martin; Damaris J Rohsenow; Jennifer W Tidey
Journal:  J Subst Abuse Treat       Date:  2019-06-10

Review 9.  Illicit dopamine transients: reconciling actions of abused drugs.

Authors:  Dan P Covey; Mitchell F Roitman; Paul A Garris
Journal:  Trends Neurosci       Date:  2014-03-20       Impact factor: 13.837

10.  Prosocial effects of nicotine and ethanol in adolescent rats through partially dissociable neurobehavioral mechanisms.

Authors:  Viviana Trezza; Petra J J Baarendse; Louk J M J Vanderschuren
Journal:  Neuropsychopharmacology       Date:  2009-08-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.